Breaking News

Otsuka Acquires Rights to Eisai’s Dacogen

March 31, 2014

Gains development and commercialization rights in the U.S., Canada and Japan

Eisai, Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., has sold the rights to DACOGEN (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd. DACOGEN is approved for treatment of patients with myelodysplastic syndromes
Through an exclusive worldwide license, Otsuka gains full development and commercialization rights for the product in the former Eisai territories of the U.S., Canada and Japan. Eisai will retain its rights for DACOGEN in Mexico. Otsuka will also gain the patent for Eisai’s metabolic enzyme inhibitor E7727.
Eisai's marketing rights for DACOGEN originate from a worldwide license from Astex Pharmaceuticals, Inc., which was acquired by Otsuka in October 2013.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more